CA3073983C - Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds - Google Patents

Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds Download PDF

Info

Publication number
CA3073983C
CA3073983C CA3073983A CA3073983A CA3073983C CA 3073983 C CA3073983 C CA 3073983C CA 3073983 A CA3073983 A CA 3073983A CA 3073983 A CA3073983 A CA 3073983A CA 3073983 C CA3073983 C CA 3073983C
Authority
CA
Canada
Prior art keywords
methyl
pyrazol
phenyl
amino
cyclopropanecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3073983A
Other languages
English (en)
French (fr)
Other versions
CA3073983A1 (en
Inventor
Tianwei Ma
Liang Wu
Xuejun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3073983A1 publication Critical patent/CA3073983A1/en
Application granted granted Critical
Publication of CA3073983C publication Critical patent/CA3073983C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3073983A 2017-09-04 2018-08-28 Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds Active CA3073983C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/100354 2017-09-04
PCT/CN2017/100354 WO2019041340A1 (en) 2017-09-04 2017-09-04 LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)
PCT/US2018/048249 WO2019046239A1 (en) 2017-09-04 2018-08-28 LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)

Publications (2)

Publication Number Publication Date
CA3073983A1 CA3073983A1 (en) 2019-03-07
CA3073983C true CA3073983C (en) 2023-10-17

Family

ID=63528947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073983A Active CA3073983C (en) 2017-09-04 2018-08-28 Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds

Country Status (13)

Country Link
US (2) US11365185B2 (enExample)
EP (1) EP3679032B1 (enExample)
JP (1) JP6854386B2 (enExample)
KR (1) KR102341064B1 (enExample)
CN (1) CN111032647B (enExample)
AU (1) AU2018323969B2 (enExample)
CA (1) CA3073983C (enExample)
EA (1) EA039482B1 (enExample)
ES (1) ES2966827T3 (enExample)
IL (1) IL273000B2 (enExample)
MX (1) MX2020002430A (enExample)
SA (1) SA520411406B1 (enExample)
WO (2) WO2019041340A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
CN113461640B (zh) * 2021-06-17 2023-08-11 中央民族大学 Lpar1抑制剂、医药用途及其制备方法
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
JP2025540714A (ja) * 2022-11-24 2025-12-16 ローツェ・バイオ・インコーポレイテッド Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
CN121419961A (zh) * 2023-06-02 2026-01-27 迈塔免疫科技股份有限公司 用于治疗纤维化疾病的化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) * 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
CN103596947A (zh) * 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9526091B2 (en) * 2012-03-16 2016-12-20 Intel Corporation Method and apparatus for coordination of self-optimization functions in a wireless network
JPWO2017086430A1 (ja) * 2015-11-20 2018-09-06 宇部興産株式会社 Ｎａｓｈの治療又は予防のための医薬組成物

Also Published As

Publication number Publication date
US20220281845A1 (en) 2022-09-08
KR102341064B1 (ko) 2021-12-20
ES2966827T3 (es) 2024-04-24
AU2018323969B2 (en) 2020-07-16
EP3679032A1 (en) 2020-07-15
EA039482B1 (ru) 2022-02-01
KR20200035440A (ko) 2020-04-03
CA3073983A1 (en) 2019-03-07
WO2019046239A1 (en) 2019-03-07
WO2019041340A1 (en) 2019-03-07
EA202090368A1 (ru) 2020-06-09
US11365185B2 (en) 2022-06-21
IL273000A (en) 2020-04-30
JP2020532550A (ja) 2020-11-12
US12145924B2 (en) 2024-11-19
AU2018323969A1 (en) 2020-02-20
CN111032647A (zh) 2020-04-17
BR112020002217A2 (pt) 2020-07-28
US20200231568A1 (en) 2020-07-23
EP3679032B1 (en) 2023-10-04
SA520411406B1 (ar) 2022-08-28
IL273000B2 (en) 2023-08-01
JP6854386B2 (ja) 2021-04-07
CN111032647B (zh) 2023-05-02
MX2020002430A (es) 2020-07-13
IL273000B1 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
US12145924B2 (en) Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
TWI767410B (zh) 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途
US9382228B2 (en) N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
TWI417096B (zh) 用於發炎及免疫相關用途之苯基及吡啶基化合物
RU2576619C2 (ru) Способ получения пиримидиновых производных
EP2848610A1 (en) Inhibitors of kinase activity
US20240317726A1 (en) Novel lxr modulators with bicyclic core moiety
KR20110091865A (ko) ２ｈ-크로멘 화합물 및 그의 유도체
CN104411690A (zh) 作为lpar拮抗剂的取代的吡唑化合物
CN106660968B (zh) 吡唑衍生物及其作为大麻素受体介体的用途
US20220227730A1 (en) Treatment of fibrosis with ire1 small molecule inhibitors
IL296632A (en) phd inhibitory compounds, compositions and use
JP2025540714A (ja) Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
CA3253274A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT
CN104334528A (zh) (2-杂芳基氨基)琥珀酸衍生物
JP2014532656A (ja) 炎症および免疫関連用途のための化合物
BR112020002217B1 (pt) Compostos inibidores do receptor de ácido lisfosfatídico 1 (lpar1)
CN107207407A (zh) 用于治疗疾病和病症的组合物和方法
HK1220400B (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200226

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724